PMID- 38252529
OWN - NLM
STAT- MEDLINE
DCOM- 20240313
LR  - 20240313
IS  - 1553-3514 (Electronic)
IS  - 1553-3506 (Linking)
VI  - 31
IP  - 2
DP  - 2024 Apr
TI  - A Matched Comparative Analysis of Type-2 Diabetes Mellitus Remission Between 
      Roux-en-Y Gastric Bypass and Sleeve Gastrectomy.
PG  - 148-156
LID - 10.1177/15533506241229040 [doi]
AB  - OBJECTIVE: Multiple scores validate long-term type-2 diabetes mellitus (T2DM) 
      remission after metabolic and bariatric surgery (MBS). However, studies comparing 
      Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) have not adequately 
      controlled for certain parameters, which may influence procedure selection. 
      METHODS: We conducted a multicenter retrospective review of patients with T2DM 
      who underwent RYGB or SG between 2008 and 2017. Data on demographics, clinical, 
      laboratory, and metabolic values were collected annually for up to 14 years. Each 
      eligible RYGB patient was individually matched to an eligible SG patient based on 
      diabetes severity, weight loss, and follow-up duration. RESULTS: Among 1149 T2DM 
      patients, 467 were eligible for matching. We found 97 matched pairs who underwent 
      RYGB or SG. RYGB showed significantly higher T2DM remission rates (46.4%) 
      compared to SG (33.0%) after matching. SG patients had higher insulin usage 
      (35.1%) than RYGB patients (20.6%). RYGB patients also experienced greater 
      decreases in HbA1c levels and diabetes medication usage than SG patients. 
      CONCLUSIONS: RYGB demonstrates higher efficacy for T2DM remission compared to SG, 
      regardless of baseline characteristics, T2DM severity, weight loss, and follow-up 
      duration. Further studies are needed to understand the long-term metabolic 
      effects of MBS and the underlying pathophysiology of T2DM remission after MBS.
FAU - Hage, Karl
AU  - Hage K
AD  - Department of Surgery, Mayo Clinic, Rochester, MN, USA. RINGGOLD: 4352
FAU - Ma, Pearl
AU  - Ma P
AD  - Fresno Heart and Surgical Hospital, UCSF Fresno, Fresno, CA, USA. RINGGOLD: 
      589388
FAU - Ghusn, Wissam
AU  - Ghusn W
AD  - Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, 
      Rochester, MN, USA. RINGGOLD: 4352
FAU - Ikemiya, Kayla
AU  - Ikemiya K
AD  - Fresno Heart and Surgical Hospital, UCSF Fresno, Fresno, CA, USA. RINGGOLD: 
      589388
FAU - Acosta, Andres
AU  - Acosta A
AD  - Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, 
      Rochester, MN, USA. RINGGOLD: 4352
FAU - Vierkant, Robert A
AU  - Vierkant RA
AD  - Division of Clinical Trials and Biostatistics, Department of Quantitative Health 
      Sciences, Mayo Clinic, Rochester, MN, USA. RINGGOLD: 4352
FAU - Abu Dayyeh, Barham K
AU  - Abu Dayyeh BK
AD  - Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, 
      Rochester, MN, USA. RINGGOLD: 4352
FAU - Higa, Kelvin D
AU  - Higa KD
AD  - Fresno Heart and Surgical Hospital, UCSF Fresno, Fresno, CA, USA. RINGGOLD: 
      589388
FAU - Ghanem, Omar M
AU  - Ghanem OM
AD  - Department of Surgery, Mayo Clinic, Rochester, MN, USA. RINGGOLD: 4352
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20240122
PL  - United States
TA  - Surg Innov
JT  - Surgical innovation
JID - 101233809
SB  - IM
MH  - Humans
MH  - *Gastric Bypass/methods
MH  - *Diabetes Mellitus, Type 2/surgery
MH  - Retrospective Studies
MH  - Gastrectomy/methods
MH  - Weight Loss
MH  - *Obesity, Morbid/surgery
MH  - Treatment Outcome
OTO - NOTNLM
OT  - individualized metabolic surgery
OT  - obesity
OT  - roux-en-Y gastric bypass
OT  - sleeve gastrectomy
OT  - type-2 diabetes
COIS- Declaration of Conflicting InterestsThe author(s) declared the following 
      potential conflicts of interest with respect to the research, authorship, and/or 
      publication of this article: Dr Pearl Ma is a consultant for Ethicon, Medtronic 
      and Intuitive. Dr Andres Acosta reported receiving grants from the National 
      Institute of Diabetes and Digestive and Kidney Diseases during the conduct of the 
      study; holding stock in Gila Therapeutics and Phenomix Sciences; and serving as a 
      consultant for Rhythm Pharmaceuticals, General Mills, and Amgen Pharmaceuticals 
      outside the submitted work. Dr Barham Abu Dayyeh has received consulting fee from 
      Endogenex, Endo-TAGSS, Metamodix, and BFKW; consulting fee and grant/research 
      support from USGI, Cairn Diagnostics, Aspire Bariatrics, Boston Scientific; 
      speaker honorarium from Olympus, Johnson and Johnson; speaker honorarium and 
      grant/research support from Medtronic, Endogastric solutions; and research 
      support/grant from Apollo Endosurgery, and Spatz Medical. Dr Kelvin Higa is a 
      consultant for Medtronic and Ethicon. Dr Karl Hage, Dr Wissam Ghusn, Kayla 
      Ikemiya, Robert A. Vierkant, and Dr Omar M. Ghanem declare no conflict of 
      interest.
EDAT- 2024/01/22 18:42
MHDA- 2024/03/13 06:47
CRDT- 2024/01/22 12:33
PHST- 2024/03/13 06:47 [medline]
PHST- 2024/01/22 18:42 [pubmed]
PHST- 2024/01/22 12:33 [entrez]
AID - 10.1177/15533506241229040 [doi]
PST - ppublish
SO  - Surg Innov. 2024 Apr;31(2):148-156. doi: 10.1177/15533506241229040. Epub 2024 Jan 
      22.